165 related articles for article (PubMed ID: 21750219)
1. PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity.
Yuan J; Mehta PP; Yin MJ; Sun S; Zou A; Chen J; Rafidi K; Feng Z; Nickel J; Engebretsen J; Hallin J; Blasina A; Zhang E; Nguyen L; Sun M; Vogt PK; McHarg A; Cheng H; Christensen JG; Kan JL; Bagrodia S
Mol Cancer Ther; 2011 Nov; 10(11):2189-99. PubMed ID: 21750219
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423.
Kashiyama T; Oda K; Ikeda Y; Shiose Y; Hirota Y; Inaba K; Makii C; Kurikawa R; Miyasaka A; Koso T; Fukuda T; Tanikawa M; Shoji K; Sone K; Arimoto T; Wada-Hiraike O; Kawana K; Nakagawa S; Matsuda K; McCormick F; Aburatani H; Yano T; Osuga Y; Fujii T
PLoS One; 2014; 9(2):e87220. PubMed ID: 24504419
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the dual mTOR/PI3K inhibitors Gedatolisib (PF-05212384) and PF-04691502 against ovarian cancer xenograft models.
Langdon SP; Kay C; Um IH; Dodds M; Muir M; Sellar G; Kan J; Gourley C; Harrison DJ
Sci Rep; 2019 Dec; 9(1):18742. PubMed ID: 31822716
[TBL] [Abstract][Full Text] [Related]
4. The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in
Ippen FM; Alvarez-Breckenridge CA; Kuter BM; Fink AL; Bihun IV; Lastrapes M; Penson T; Schmidt SP; Wojtkiewicz GR; Ning J; Subramanian M; Giobbie-Hurder A; Martinez-Lage M; Carter SL; Cahill DP; Wakimoto H; Brastianos PK
Clin Cancer Res; 2019 Jun; 25(11):3374-3383. PubMed ID: 30796030
[TBL] [Abstract][Full Text] [Related]
5. First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer.
Shapiro GI; Bell-McGuinn KM; Molina JR; Bendell J; Spicer J; Kwak EL; Pandya SS; Millham R; Borzillo G; Pierce KJ; Han L; Houk BE; Gallo JD; Alsina M; Braña I; Tabernero J
Clin Cancer Res; 2015 Apr; 21(8):1888-95. PubMed ID: 25652454
[TBL] [Abstract][Full Text] [Related]
6. CBF-Beta Mitigates PI3K-Alpha-Specific Inhibitor Killing through PIM1 in PIK3CA-Mutant Gastric Cancer.
Stanland LJ; Ang HX; Hoj JP; Chu Y; Tan P; Wood KC; Luftig MA
Mol Cancer Res; 2023 Nov; 21(11):1148-1162. PubMed ID: 37493631
[TBL] [Abstract][Full Text] [Related]
7. Design, Synthesis, Formulation, and Bioevaluation of Trisubstituted Triazines as Highly Selective mTOR Inhibitors for the Treatment of Human Breast Cancer.
Sun Q; Chu Y; Zhang N; Chen R; Wang L; Wu J; Dong Y; Li H; Wang L; Tang L; Zhan C; Zhang JQ
J Med Chem; 2024 May; 67(9):7330-7358. PubMed ID: 38661655
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy of prostate cancer with HPMA copolymer conjugates containing PI3K/mTOR inhibitor and docetaxel.
Zhou Y; Yang J; Zhang R; Kopeček J
Eur J Pharm Biopharm; 2015 Jan; 89():107-15. PubMed ID: 25481033
[TBL] [Abstract][Full Text] [Related]
9. Recent syntheses of PI3K/Akt/mTOR signaling pathway inhibitors.
Welker ME; Kulik G
Bioorg Med Chem; 2013 Jul; 21(14):4063-91. PubMed ID: 23735831
[TBL] [Abstract][Full Text] [Related]
10. Dual Targeting of CDK4 and ARK5 Using a Novel Kinase Inhibitor ON123300 Exerts Potent Anticancer Activity against Multiple Myeloma.
Perumal D; Kuo PY; Leshchenko VV; Jiang Z; Divakar SK; Cho HJ; Chari A; Brody J; Reddy MV; Zhang W; Reddy EP; Jagannath S; Parekh S
Cancer Res; 2016 Mar; 76(5):1225-36. PubMed ID: 26873845
[TBL] [Abstract][Full Text] [Related]
11. PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects.
Mishra R; Patel H; Alanazi S; Kilroy MK; Garrett JT
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33801659
[TBL] [Abstract][Full Text] [Related]
12. Drugging the PI3 kinome: from chemical tools to drugs in the clinic.
Workman P; Clarke PA; Raynaud FI; van Montfort RL
Cancer Res; 2010 Mar; 70(6):2146-57. PubMed ID: 20179189
[TBL] [Abstract][Full Text] [Related]
13. Identification of 4-phenylquinolin-2(1H)-one as a specific allosteric inhibitor of Akt.
Huang BX; Newcomer K; Kevala K; Barnaeva E; Zheng W; Hu X; Patnaik S; Southall N; Marugan J; Ferrer M; Kim HY
Sci Rep; 2017 Sep; 7(1):11673. PubMed ID: 28916818
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and tissue distribution study of two novel quinazoline PI3K/mTOR dual-inhibitors, potential anticancer agents.
Chen J; Bian X; Zhang S; Yang G
Pak J Pharm Sci; 2023 Sep; 36(5):1527-1542. PubMed ID: 37869929
[TBL] [Abstract][Full Text] [Related]
15. β-carboline derivative Z86 attenuates colorectal cancer cell proliferation and migration by directly targeting PI3K.
Nie S; Chang L; Huang Y; Zhou H; Yang Q; Kong L; Li Y
Nat Prod Bioprospect; 2024 Jan; 14(1):3. PubMed ID: 38169019
[TBL] [Abstract][Full Text] [Related]
16. Genetic Silencing of AKT Induces Melanoma Cell Death via mTOR Suppression.
Parkman GL; Turapov T; Kircher DA; Burnett WJ; Stehn CM; O'Toole K; Culver KM; Chadwick AT; Elmer RC; Flaherty R; Stanley KA; Foth M; Lum DH; Judson-Torres RL; Friend JE; VanBrocklin MW; McMahon M; Holmen SL
Mol Cancer Ther; 2024 Mar; 23(3):301-315. PubMed ID: 37931033
[TBL] [Abstract][Full Text] [Related]
17. Non-Clinical Toxicology Evaluation of the Novel Non-ATP Competitive Oral PI3 Kinase Delta Inhibitor Roginolisib.
van der Veen L; Schmitt M; Deken MA; Lahn M
Int J Toxicol; 2023 Dec; 42(6):515-534. PubMed ID: 37667445
[TBL] [Abstract][Full Text] [Related]
18. Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors.
Shuttleworth SJ; Silva FA; Cecil AR; Tomassi CD; Hill TJ; Raynaud FI; Clarke PA; Workman P
Curr Med Chem; 2011; 18(18):2686-714. PubMed ID: 21649578
[TBL] [Abstract][Full Text] [Related]
19. Rationale-based therapeutic combinations with PI3K inhibitors in cancer treatment.
Castel P; Toska E; Zumsteg ZS; Carmona FJ; Elkabets M; Bosch A; Scaltriti M
Mol Cell Oncol; 2014; 1(3):e963447. PubMed ID: 27308344
[TBL] [Abstract][Full Text] [Related]
20. Discovery and Biological Profiling of Potent and Selective mTOR Inhibitor GDC-0349.
Pei Z; Blackwood E; Liu L; Malek S; Belvin M; Koehler MF; Ortwine DF; Chen H; Cohen F; Kenny JR; Bergeron P; Lau K; Ly C; Zhao X; Estrada AA; Truong T; Epler JA; Nonomiya J; Trinh L; Sideris S; Lesnick J; Bao L; Vijapurkar U; Mukadam S; Tay S; Deshmukh G; Chen YH; Ding X; Friedman LS; Lyssikatos JP
ACS Med Chem Lett; 2013 Jan; 4(1):103-7. PubMed ID: 24900569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
